单克隆抗体与阿霉素偶联物介入治疗胃癌

Bio-Targeting Immunothrapy For Patients with Gastric Cancer Using Conjuneate of Adri-amycin with Monoclonal Anti-Transferrin Recptor Antibody

目的:了解转铁蛋白受体单克隆抗体与阿霉素偶联,制成阿霉素单抗偶联物,分别通过胃镜下瘤体直接注射,动脉插管灌注和静脉输注三种方法治疗对胃癌的疗效 方法:采用30%氧化葡聚糖偶联法,将转铁蛋白受体单克隆抗体与阿霉素通过葡聚糖Dextran-10按一定程序偶联.将阿霉素单抗偶联物分别通过胃镜下注射、动脉插管灌注和静脉输注三种方法治疗胃癌共同46例 结果:胃镜下注射、动脉插管灌注和静脉输注三种方法的总缓解率分别为46.67%(7/15),56.25%(9/16)和33.33%(5/15)出现毒副反应的例数分别3例,5例和6例.统计学比较,胃镜下注射组疗效与动脉插管灌注组无明显差异(p>0 05),比静脉输注组效果好(p<0.05),而毒副作用方而则前组明显少于后两组(P<0.05)结论:胃镜下瘤体直接注射与动脉插管灌注单抗偶联化疗药物治疗胃癌效果好。

Objective: To study the effects of advanced gastric cancer which were treated with the conjugation of Adriamycin with monoclonal anti - transferrin receptor antibody (Adr - TFR-M) by endoscopy, and by X - ray and by routine iv drip therapy. Methods: The Adr-TFR-M was prepared via30% oxidized Dextran T10.31 patients with advanced gastric cancer were treated with Adr-TFR-M by endoscopy (15cases, A group) and by X - ray (16 cases B group) , and compared with 15 cases used by routine iv drip (C group) therapy.Results:The results showed that there were CR 0 case PR 7 cases, NC 4 cases, PD 4 cases in A group; CR 1 case, PR 8 cases, NC 4 cases,PD 3 cases in B group;CR Ocases,PR 5 cases,NC 6 cases,PD 4 cases in C group.The total effective rate was 46.67 % , 56.25 % and 33.33 % in A group , in B group and in C group, respectively (A group vs B group p>0.05, A group or B group vs C group p<0.05). Conclusion: The Adr-TFR-M is effective in the treatment of Gastric cancer and has more effective by endoscopy or by X - ray than that by routine iv drip therapy.